NCIt definition : A humanized monoclonal antibody directed against the transforming growth factor beta
(TGFbeta) activator, glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing
protein 32; LRRC32), with potential immunomodulating and antineoplastic activities.
Upon administration, livmoniplimab selectively targets and binds to GARP which interferes
with the production and release of active TGFbeta by regulatory T-cells (Tregs). Selective
inhibition of the release of TGFbeta from Tregs leads to a reversal of immunosuppression
thereby increasing the immune response to tumor cells. GARP, a leucine-rich repeat-containing
protein, is essential for the expression of TGFbeta on the cell surface of activated
Tregs; it plays an important role in regulation of the immune cell function.;
UNII : 42SH7JCD82;
CAS number : 2412004-88-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2412004-88-5
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : ABBV 151; ARGX 115; ARGX-115; ABBV-151;
Semantic type(s)